QCM Cayman’s PTC Therapeutics PTCT Stock Holding History

QCM Cayman’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-5,638	Closed	-$271K	–	275
2015 Q2	$271K	Buy	+5,638	New	+$329K	0.1%	106

Other funds holding PTCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

QCM Cayman's PTCT Position: Q3 2015 in Review

QCM Cayman sold out of PTC Therapeutics (PTCT) in Q3 2015, closing a stake of 5,638 shares — an estimated $271K sold.

QCM Cayman first reported a position in PTCT in Q2 2015 and held it in 1 quarter. The position peaked at $271K in Q2 2015. 157 funds tracked by Wall St. Rank hold PTCT as of Q3 2015.

QCM Cayman reported no remaining PTC Therapeutics position as of Q3 2015 after selling out during the quarter.
QCM Cayman sold 5,638 PTC Therapeutics shares in Q3 2015, an estimated $271K.
QCM Cayman first reported a position in PTC Therapeutics in Q2 2015 and held it in 1 quarter.
QCM Cayman's PTC Therapeutics position peaked at $271K in Q2 2015.
157 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2015.

Based on QCM Cayman's 13F filing for Q3 2015, filed 16 Nov 2015.